Our news

• Pfizer and NovaMedica Complete Strategic Partnership Agreement for the Technology Transfer of 30 Key Medicines

  23 December 2016

  

  Pfizer Inc, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have completed the last stage of negotiations for a long-term strategic partnership designed to transfer the rights and technologies for the production of more than 30 life-saving and essential drugs from the Pfizer product portfolio. The deal will enable Pfizer and NovaMedica to improve the health of patients in Russia and modernize the Russian pharmaceutical industry.

• NovaMedica prepares to launch the new drug development laboratories

  10 November 2016

  

  Russian pharmaceutical company NovaMedica launches R&D laboratories as part of its Technology Center project for the development and pilot production of innovative drugs. The facilities are designed to address the most challenging scientific tasks based on the state-of-the-art platforms incorporating nanotechnologies. The project investment totals $15m.                                                   

• Four NovaMedica Executives are in the Top-1000 Russian Managers Rating Released by the Managers Association of Russia and Kommersant Publishing House

  03 October 2016

  

  Four NovaMedica executives are among the business leaders listed in the Top-1000 Russian Managers rating released annually by the Managers Association of Russia and Kommersant Publishing House.

• NovaMedica Strengthens its Team

  27 July 2016

  

  Russian pharmaceutical company NovaMedica announces strengthening of its team. Elena Ilyina formerly holding one of the key positions in Sun Pharma (Ranbaxy) Russia is appointed as Vice President, Business Development.

• Photo: Pfizer and NovaMedica announce a strategic partnership in Russia

  13 July 2016

  

  Pfizer, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have entered into an agreement to cooperate, signalling the development of a new partnership. Through this partnership, Pfizer proposes to invest in NovaMedica’s construction of a new manufacturing plant in the Kaluga region and license the technology for production of more than 30 medicinal products from its portfolio to the Russian partner.

• Pfizer and NovaMedica announce a strategic partnership in Russia

  13 July 2016

  

  Pfizer, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have announced the start of a long-term strategic partnership to locally manufacture and bring to the Russian market a number of important medicines. The first step will be the construction of a modern pharmaceutical manufacturing plant located in the Vorsino industrial park, Kaluga Region. 

• NovaMedica is starting construction of R&D Center for drug development using nanotechnologies

  15 December 2015

  

  NovaMedica, a Russian pharmaceutical company, is starting construction of R&D Center for innovative drug development and pilot production in Moscow. This Center will include laboratories and production areas equipped with state-of-the-art process equipment that has never been used in the Russian pharmaceutical industry before. The total investments are estimated approximately $15 million.

• NovaMedica is sharing knowledge

  29 September 2015

  

  NovaMedica actively involved in RNOF-2015 (Russian National Ophthalmological Forum) that took place in Moscow, September 23, 2015. This is one of the most important educational events in ophthalmology.

• Cortiment launched in Russia

  22 September 2015

  

  September 17, 2015, Moscow held IBD School (Inflammatory Bowel Disorder School) chaired by the head gastroenterologist of the Moscow Region, Professor Elena Belousova. NovaMedica was the general partner of this educational event that brought together over 100 gastroenterologists from Moscow and other regions of Russia.

• NovaMedica opens the program of scientific-practical events for Russian gastroenterologists

  16 July 2015

  

  Russian pharmaceutical company NovaMedica takes an active part in the V Baikal Forum on Inflammatory Bowel Diseases (IBD), which befalls from 16 to 18 of July in Irkutsk. Participating in this event NovaMedica opens a series of scientific and practical programs for the professional community of gastroenterologists.